Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from COLL

3 Pharma Stocks Primed for May Investment Opportunities

The pharma industry is poised for tremendous growth driven by surging healthcare needs, the introduction of groundbreaking medications, and relentless technological innovation. Hence, quality pharma stocks Collegium Pharmaceutical (COLL), Green Thumb Industries (GTBIF), and Bristol-Myers Squibb (BMY) emerge as prime investment options this month. Read more….

StockNews.com

3 Popular Pharma Stocks Worth Buying Now

The pharmaceutical industry is set for solid growth due to increased demand for effective treatments for regular and rare diseases, an aging population, and ongoing innovations in pharma technology. Hence, investors could consider buying quality pharmaceutical stocks such as Collegium Pharmaceutical (COLL), Novo Nordisk (NVO), and GSK (GSK). Read on.

StockNews.com

Top 3 Pharma Innovators to Watch Closely

The pharmaceutical industry is experiencing considerable growth, driven by rising healthcare needs, continuous advances in drug discovery & discovery, and M&A activity. So, investors could keep a close eye on top pharma stocks Amneal Pharmaceuticals (AMRX), Collegium Pharmaceutical (COLL), and Sanofi (SNY) for potential gains. Keep reading….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Pharma Powerhouses for Long-Term Growth in 2024

Amid evolving technologies and strategic maneuvers, the pharma industry is set for paradigm-shifting growth, propelled by growing funding and drug discovery. Hence, fundamentally strong pharma stocks Collegium Pharmaceutical (COLL), AstraZeneca (AZN), and Merck & Co. (MRK) might be ideal buys this year for long-term growth. Read more….

StockNews.com

Pharma Stocks Analysis: Grab, Hold, or Sell?

Despite economic pressures and intensified competition, government incentives and drug innovations are fueling growth in the pharma sector. So, let us delve into the analysis of leading pharma stocks Bristol-Myers Squibb (BMY), Collegium Pharmaceutical (COLL), Pfizer (PFE), and Vaxcyte (PCVX), assessing whether to Grab, Hold, or Sell the stocks amid…

StockNews.com

3 Smart Pharma Picks Serving Gains

With rising healthcare expenditure, growing need for precision medicine, innovations in biologics and gene editing, and rapid adoption of advanced technologies, the pharma industry is well-poised for significant growth and expansion. Thus, quality pharma stocks Wave Life (WVE), Teva Pharmaceuticals (TEVA), and Collegium (COLL) could be smart buys for substantial…

StockNews.com

3 Pharma Stock Buys for Last-Minute Year-End Profits

Growing healthcare spending and the use of cutting-edge technologies in the research and development of new drugs have put the pharmaceutical industry in a strong position for growth. With such constructive trends in mind, it's wise to buy fundamentally strong pharma stocks, Merck (MRK), Collegium (COLL) and Johnson & Johnson…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Are These 3 Pharma Stocks Smart Buys for Bullish Investors?

The pharmaceutical industry's outlook looks promising, given robust healthcare spending worldwide and the rapid adoption of advanced digital technologies. Amid this, let’s find out if pharma stocks AbbVie (ABBV), Collegium Pharmaceutical (COLL), and Merck (MRK) are ideal buys now. Read on to know more….

StockNews.com

3 Pharma Stocks Flashing 'Buy' Signals in December

The pharmaceutical industry is well-positioned for robust growth, driven by growing healthcare expenditure globally and the rapid adoption of digital technologies. Given the industry’s tailwinds, fundamentally strong pharma stocks, Collegium Pharmaceutical (COLL), Eton Pharmaceuticals (ETON), and GSK plc (GSK) could be ideal buys this month. Continue Reading….

StockNews.com

3 Pharma Stocks Ready to Shine This Week

The pharmaceutical industry is expected to thrive, driven by the increasing need for chronic disease management and the requirements of an aging demographic. Given the industry’s solid prospects, quality pharma stocks Organon (OGN), GoodRx Holdings (GDRX), and Collegium Pharmaceutical (COLL) could be solid buys this week. Read on….

StockNews.com

A Little Known Strategy Indicates These Three Companies Could Explode!

In this article, we look at price action strategies and uncover three companies with the potential for a breakout.

Barchart

Top 3 Pharma Stocks With Promising Prospects for October

The pharmaceutical sector is expected to grow rapidly in the coming years, owing to rising worldwide medical needs. Given the industry’s solid prospects, investors could consider buying quality pharma stocks such as Eagle Pharmaceuticals (EGRX), Organon (OGN), and Collegium Pharmaceutical (COLL) this month. Read on.

StockNews.com

Which of These 3 Pharma Stocks Are a Buy?

The pharma industry is expected to experience substantial growth in the coming years with expanding global medical needs. So, which of these pharma stocks, Ipsen (IPSEY), Collegium Pharmaceutical (COLL), and SNDL (SNDL), are a buy now? Keep reading.

StockNews.com

Canopy Growth (CGC) vs. Collegium Pharmaceutical (COLL): Which Pharma Stock Is the Better Buy for Growth Investors?

The pharma industry is poised for long-term growth supported by increasing demand for drugs worldwide and technological advancements. While leading pharma stocks Collegium Pharmaceutical (COLL) and Canopy Growth (CGC) should benefit from the industry tailwinds, let us determine which is the better buy.

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Pharma Stocks to Buy for a Smart Investment

With the rise of chronic diseases and technological advancements, the pharma market looks poised for substantial expansion. So, fundamentally strong pharma stocks Kiniksa Pharmaceuticals (KNSA), Collegium Pharmaceutical (COLL), and Wave Life Sciences (WVE) might be solid buys. Keep reading.

Benzinga

Recap: Collegium Pharmaceutical Q1 Earnings

Collegium Pharmaceutical (NASDAQ:COLL) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Benzinga

A Preview Of Collegium Pharmaceutical's Earnings

Collegium Pharmaceutical (NASDAQ:COLL) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Collegium Pharmaceutical will report an earnings per share (EPS) of $0.90.

Benzinga

Why Collegium Pharmaceutical's Shares Are Trading Higher Today

Collegium Pharmaceutical Inc (NASDAQ:COLL) updated financial guidance for FY22 to include the expected impact of the BioDelivery Sciences International Inc (BDSI) acquisition. "Near-term, we are laser-focused on seamless integration of BDSI, maximizing the potential of the portfolio, renegotiation of Xtampza ER contracts to ensure <65% gross-to-nets by January 2023, and allocating capital to…

Get all your
news in one place.

100’s of premium titles.
One news app.

People

Sristi Suman JayaswalThe

216 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

BristolMyers Squibb Company

92 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.